NCT03866382 2026-03-18
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
48 trialsNCT04981509 2026-03-18
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06863311 2026-03-16
EXACT
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06708949 2026-03-13
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07469683 2026-03-13
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
Phase 2 Recruiting
NCT06699602 2026-03-04
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07223541 2026-03-02
LAG-BOOST
University of Oklahoma
Phase 2 Recruiting
NCT06940518 2026-02-27
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07188896 2026-02-23
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04006522 2026-02-20
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT05155033 2026-02-17
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05641935 2026-02-17
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
Thomas Jefferson University
Phase 2 Recruiting
NCT07389629 2026-02-05
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Recruiting
NCT07386158 2026-02-04
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Recruiting
NCT07077161 2026-01-28
SKIPPY 2
Leiden University Medical Center
Phase 2 Recruiting
NCT05327686 2026-01-14
SAMURAI
NRG Oncology
Phase 2 Recruiting
NCT04299646 2026-01-13
GETUG-StORM-01
Centre Francois Baclesse
Phase 2 Recruiting
NCT05830058 2026-01-05
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
Phase 2 Recruiting
NCT07187778 2026-01-05
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06680089 2025-12-31
CD70-targeted immunoPET Imaging of Kidney Cancer
RenJi Hospital
Phase 2 Recruiting
NCT07285044 2025-12-22
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT04974671 2025-12-04
Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
Yale University
Phase 2 Recruiting
NCT06265285 2025-12-04
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
Phase 2 Recruiting
NCT05263050 2025-12-03
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Recruiting
NCT06601296 2025-11-12
SPARK
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07223424 2025-11-10
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT06005818 2025-10-21
MRD GATE RCC
University of Alabama at Birmingham
Phase 2 Recruiting
NCT05931393 2025-10-10
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
University of Texas Southwestern Medical Center
Phase 2 Recruiting
NCT07172386 2025-09-16
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT07175480 2025-09-16
Perfumer
Jinling Hospital, China
Phase 2 Recruiting
NCT07167329 2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2 Recruiting
NCT06302569 2025-09-09
REPRINT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Recruiting
NCT06255223 2025-09-03
A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy
Jinling Hospital, China
Phase 2 Recruiting
NCT05361720 2025-07-23
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT06642220 2025-07-20
ARRCC
Western University, Canada
Phase 2 Recruiting
NCT06447103 2025-06-12
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT05127824 2025-05-04
Autologous Dendritic Cell Vaccine in Kidney Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT04322955 2025-04-25
Cyto-KIK
Columbia University
Phase 2 Recruiting
NCT05969496 2025-04-04
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT06376669 2025-03-26
SPARE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT03786796 2025-03-13
ORCHID
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06281678 2024-12-19
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Recruiting
NCT06730672 2024-12-18
An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus
Sun Yat-sen University
Phase 2 Recruiting
NCT06211114 2024-11-26
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
Phase 2 Recruiting
NCT05024318 2024-05-16
NAPSTER
Peter MacCallum Cancer Centre, Australia
Phase 2 Recruiting
NCT06211790 2024-01-18
Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma
Fudan University
Phase 2 Recruiting
NCT05865730 2023-05-19
A Study of Oncobax®-AK in Patients With Advanced Solid Tumors
EverImmune
Phase 2 Recruiting
NCT05817903 2023-05-08
AxIn
Consorzio Oncotech
Phase 2 Recruiting